Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.


TSX:CPH - Post by User

Comment by GJS471on Mar 09, 2023 10:01am
249 Views
Post# 35327925

RE:CPH: Outperformer, Give Credit When Credit Is Due

RE:CPH: Outperformer, Give Credit When Credit Is Due
As we approach another quarterly earnings announcement, I just wanted to say that as a long time investor, my numbers are not yours.  It has been what I classify as a "faith" investment from several years ago.  I thought the Sr. Mull knew what he was doing.  It apperas he did not from an earnings and stock price perspectiive from the history of stock prices.. 
But I drank the coolaid  many years ago at a much higher cost than you  have.  I stayed in because there was so little down side.   But I am wary of new promises.  Results count.  And it has been  bleak for some time.  
I hope good reulsts for everyone this time round. 
<< Previous
Bullboard Posts
Next >>